Efficacy and Safety of Minocycline in the Treatment of Intracerebral Hemorrhage

Official title

Efficacy and Safety of Minocycline in the Treatment of Intracerebral Hemorrhage: a Multicenter, Randomized, Open-label, Blinded Endpoint Clinical Study

Overview

This study plans to enroll 1248 patients with supratentorial ICH within 24 hours of onset across multiple stroke centers. After randomization, the control group will only receive medical therapy. The experimental group, after randomization, will receive an initial dose of 200 mg of minocycline hydrochloride capsules in addition to medical ttherapy, followed by 100 mg orally every 12 hours for 7 days, resulting in a total of 14 administrations. Both groups will be followed for 180 days to evaluate the efficacy and safety of minocycline in the treatment of ICH.

Interventions

• Drug Minocycline
  The experimental group will receive an initial dose of 200 mg of minocycline hydrochloride capsules in addition to medical therapy after randomization, followed by 100 mg orally every 12 hours for 7 days, totaling 14 administrations.

Primary outcome measures

• The proportion of patients with favorable functional outcomes, defined as mRS 0-2 at 180 days. [Time frame: 180 days]

Secondary outcome measures (5)

• The proportion of patients with an mRS score of 0-1 at 180 days. [Time frame: 180 days]
• The proportion of patients with favorable functional outcome (mRS score of 0-2) at 90 days. [Time frame: 90 days]
• The proportion of patients with an mRS score of 0-1 at 90 days. [Time frame: 90 days]
• The distribution of mRS scores at 90 days and 180 days. [Time frame: 90 days and 180 days]
• The NIHSS scores after 7 days of treatment. [Time frame: 7 days]

Eligibility criteria

Inclusion criteria

• Age ≥ 18 years, regardless of gender;
• Supratentorial ICH confirmed by brain CT scan;
• No disability in the community before ICH (premorbid mRS≤1);
• Neurological deficits related to the hematoma, with NIHSS score ≥ 6 and single-limb motor item score ≥ 2;
• GCS score ≥ 6;
• Able to initiate the first dose of minocycline within 24 hours of onset;
• Signed and dated informed consent.

Exclusion criteria

• Definite evidence of secondary ICH, such as structural abnormality, brain aneurysm, brain tumor, use of thrombolytic drugs;
• Allergy to tetracycline antibiotics;
• Use of vitamin A derivatives or steroid therapy within the past 3 months;
• Concomitant infection requiring antibiotic treatment at admission;
• Planned surgical intervention;
• Life expectancy of less than 6 months due to comorbid conditions;
• Severe hepatic and renal dysfunction, or AST and/or ALT >3 times the upper limit of reference range, or serum creatinine >265 μmol/L (> 3 mg/dL);
• Bleeding tendency, including heparin use within the past 48 hours (APTT ≥ 35 s), oral warfarin (INR > 2), platelet count < 100 × 10⁹/L, or hereditary hemorrhagic diseases;
• Known pregnancy or breastfeeding;
• Patients being enrolled or having been enrolled in another clinical trial within the 3 months prior to this clinical trial;
• A high likelihood that the patient will not adhere to the study treatment and follow-up regimen;
• Patients unsuitable for enrollment in the clinical trial according to the investigator's discretion.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Single blind

Primary purpose

Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07305896 · Enhance

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗